161 related articles for article (PubMed ID: 30277446)
21. Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy.
Hoadley A; Sandanayake N; Long GV
Ann Oncol; 2017 Feb; 28(2):434-435. PubMed ID: 27864215
[No Abstract] [Full Text] [Related]
22. Pembrolizumab for Recurrent Conjunctival Melanoma.
Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
[No Abstract] [Full Text] [Related]
23. PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist.
Kwatra SG; Ständer S; Kang H
N Engl J Med; 2018 Oct; 379(16):1578-1579. PubMed ID: 30332571
[No Abstract] [Full Text] [Related]
24. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
25. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
[TBL] [Abstract][Full Text] [Related]
26. Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis.
Frye BC; Meiss F; von Bubnoff D; Zissel G; Müller-Quernheim J
N Engl J Med; 2020 Jun; 382(26):2573-2574. PubMed ID: 32579820
[No Abstract] [Full Text] [Related]
27. Diabetic ketoacidosis following immunotherapy for lung cancer.
Skorpen PK; Margull J
Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100
[No Abstract] [Full Text] [Related]
28. Autoimmune Polyarthritis Induced by Cancer Immunotherapy With Checkpoint Inhibitor.
Quresh Q; Quinet R
J Clin Rheumatol; 2017 Jun; 23(4):235. PubMed ID: 28538282
[No Abstract] [Full Text] [Related]
29. Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment.
Dehghani L; Mikail N; Kramkimel N; Soyer P; Lebtahi R; Mallone R; Larger E
Eur J Cancer; 2018 Nov; 104():243-246. PubMed ID: 30454710
[No Abstract] [Full Text] [Related]
30. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
Haddox CL; Shenoy N; Shah KK; Kao JC; Jain S; Halfdanarson TR; Wijdicks EF; Goetz MP
Ann Oncol; 2017 Mar; 28(3):673-675. PubMed ID: 27993808
[No Abstract] [Full Text] [Related]
31. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
32. Arterial thrombosis and anti-PD-1 blockade.
Boutros C; Scoazec JY; Mateus C; Routier E; Roy S; Robert C
Eur J Cancer; 2018 Mar; 91():164-166. PubMed ID: 29289455
[No Abstract] [Full Text] [Related]
33. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
Yatim N; Mateus C; Charles P
Rev Med Interne; 2018 Feb; 39(2):130-133. PubMed ID: 29277453
[TBL] [Abstract][Full Text] [Related]
34. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
[No Abstract] [Full Text] [Related]
35. Making precision oncology the standard of care.
The Lancet Oncology
Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
[No Abstract] [Full Text] [Related]
36. Vasculitic neuropathy induced by pembrolizumab.
Aya F; Ruiz-Esquide V; Viladot M; Font C; Prieto-González S; Prat A; Arance A
Ann Oncol; 2017 Feb; 28(2):433-434. PubMed ID: 27864214
[No Abstract] [Full Text] [Related]
37. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
38. Pembrolizumab-associated inflammatory myopathy.
Gandiga PC; Wang AR; Gonzalez-Rivera T; Sreih AG
Rheumatology (Oxford); 2018 Feb; 57(2):397-398. PubMed ID: 29088490
[No Abstract] [Full Text] [Related]
39. Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
Algaeed M; Mukharesh L; Heinzelmann M; Kaminski HJ
Neurology; 2018 Oct; 91(14):e1365-e1367. PubMed ID: 30275130
[No Abstract] [Full Text] [Related]
40. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
Amode R; Baroudjian B; Kowal A; Jebali M; Allayous C; Bagot M; Madjlessi N; Roux J; Viguier M; Basset Seguin N; Porcher R; Pagès C; Lebbé C
Melanoma Res; 2017 Apr; 27(2):110-115. PubMed ID: 27926587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]